Patent details

Basic Information

Publication number:

EP3438107

PCT Application Number:

CN2017106616

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP178696696

PCT Publication Number:

WO2018086446

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY

French Title of Invention:

COMPOSÉ QUINAZOLINE SUBSTITUÉ AYANT UNE CAPACITÉ DE PÉNÉTRATION DE BARRIÈRE HÉMATO-ENCÉPHALIQUE

German Title of Invention:

SUBSTITUIERTE CHINAZOLINVERBINDUNG MIT BLUT-HIRN-SCHRANKEN-PENETRATIONSFÄHIGKEIT

SPC Number:

Dates

Filing date:

17/10/2017

Grant date:

10/06/2020

EP Publication Date:

06/02/2019

PCT Publication Date:

17/05/2018

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

10/06/2020

EP B1 Publication Date:

10/06/2020

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

17/10/2020

Expiration date:

17/10/2037

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

03/06/2020

 

 

Name:

Weishang (Shanghai) Bio-Pharmaceutical Co., Ltd.

Address:

Room E8, 3rd Floor, Building 6 No.4299 Jindu Road Minhang District, Shanghai 201108, China (CN)

Inventor

Name:

ZHONG, Wei

Address:

China (CN)

Priority

Priority Number:

201610982608

Priority Date:

08/11/2016

Priority Country:

China (CN)

Classification

IPC classification:

A61K 31/517; A61P 25/28; A61P 35/00; C07D 401/12; C07D 405/14;

Publication

European Patent Bulletin

Issue number:

202024

Publication date:

10/06/2020

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages